Reported results
- Fourth quarter GAAP EPS was $0.23 and Adjusted EPS was $0.78.
- Fiscal 2026 GAAP EPS was $(0.05) and Adjusted EPS was $1.93.
- Fourth quarter net sales increased 3.0% and organic net sales increased 3.1%.
- Fiscal 2026 net sales increased 1.8% and organic net sales increased 0.3%.
- Fourth quarter Adjusted EBITDA was $76.8 million, compared to $43.0 million in the prior year quarter.
- Fiscal 2026 Adjusted EBITDA was $254.5 million, compared to $239.7 million in the prior year.
Guidance
- Reported net sales are expected to increase in the range of approximately 0.4% to 2.4% for fiscal 2027.
- Organic net sales are expected to increase in the range of approximately 1.0% to 3.0% for fiscal 2027.
- GAAP EPS is expected to be in the range of $0.90 to $1.20 for fiscal 2027.
- Adjusted EPS is expected to be in the range of $1.85 to $2.15 for fiscal 2027.
- Adjusted EBITDA is expected to be in the range of $250 to $270 million for fiscal 2027.
Notes
Results exclude the Feminine Care business which is treated as discontinued operations; financial results are preliminary until the Form 10-K is filed.
Price and volatility reaction
The stock moved -1.4% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 29.15 | 2026-11-11 |
| Close after release | 28.74 | 2026-11-12 |
| Realised move | -1.4% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
